2 brothers software
Two Brothers Software, Providing Ergonomic Software including utilities and games, and web optimization since 2003
Two Brothers Software
HOME
Two Brothers Software
UTILITIES
Two Brothers Software
CONTACT
Two Brothers Software Shareware
SHAREWARE
Two Brothers Software Store
STORE
divider

HOME

CONTACT US

UTILITIES

divider



divider

SHAREWARE

divider

SPYWARE STATEMENT

divider

ART AND MUSIC

divider

STORE

divider



welcome to the Two Brothers Software Games Page. From this page you can access many of the games we have designed.

Games
Current we are not supporting any games.

© Two Brothers Software






Slashdot
Slashdot
News for nerds, stuff that matters

Google Introduces HTML 5.1 Tag To Chrome
by timothy
30 Aug 2014 at 12:20am
darthcamaro (735685) writes "Forget about HTML5, that's already passe — Google is already moving on to HTML5.1 support for the upcoming Chrome 38 release. Currently only a beta, one of the biggest things that web developers will notice is the use of the new "picture" tag which is a container for multiple image sizes/formats. Bottom line is it's a new way to think about the "IMG" tag that has existed since the first HTML spec."

Read more of this story at Slashdot.









Anti-Ebola Drug ZMapp Makes Clean Sweep: 18 of 18 Monkeys Survive Infection
by timothy
29 Aug 2014 at 9:35pm
Scientific American reports, based on a study published today in Nature, that ZMapp, the drug that has been used to treat seven patients during the current Ebola epidemic in West Africa, can completely protect monkeys against the virus, research has found. ... The drug — a cocktail of three purified immune proteins, or monoclonal antibodies, that target the Ebola virus — has been given to seven people: two US and three African health-care workers, a British nurse and a Spanish priest. The priest and a Liberian health-care worker who got the drug have since died. There is no way to tell whether ZMapp has been effective in the patients who survived, because they received the drug at different times during the course of their disease and received various levels of medical care. NPR also has an interview with study lead Gary Kobinger, who says that (very cautious) human trials are in the works, and emphasizes the difficulites of producing the drug in quantity.

Read more of this story at Slashdot.










Newsfeed display by CaRP